Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem metabolic disorder with extrahepatic manifestations, including chronic kidney disease (CKD). However, population-level evidence on the renal impact of metabolic heterogeneity and fibrosis severity in...
Hyejin Park, S. Kim· Frontiers in Endocrinology· 0 citations
In CKD, recurrent CV risk is driven not only by traditional factors, particularly diabetes, but also by markers of vascular injury and inflammation, and strategies targeting both metabolic and inflammatory pathways may be critical to reducing recurrent CV burden.
Eunjeong Kang, Dha Woon Im, Minsang Kim et al.· JN. Journal of Nephrology (M...· 0 citations
The CatBoost-based ML model accurately predicts 5-year mortality in non-dialysis CKD patients using five readily available clinical parameters and it is expected that the clinical implementation of this model may offer a practical method for early risk stratification and personalized management.
Sang-He-On Suh, Hong-Sang Choi, C. Kim et al.· Kidney Research and Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.